AerovectRx Announces Scientific Advisory Board.

NORCROSS, Ga. -- AerovectRx Corporation, developer of new disposable unit dosage nebulizer drug delivery technology, announced the founding members of its Scientific Advisory Board.

Kenneth Brigham, M.D. (Chair) - Emory University School of Medicine
Robert Aris, M.D. - University of North Carolina School of Medicine
James J. Barry, Ph.D. - Creare, Inc.
Beth L. Laube, Ph.D. - Johns Hopkins University School of Medicine
Ralph Tripp, Ph.D. - University of Georgia
Gerald Smaldone, M.D., Ph.D. - State University of New York at Stony
                               Brook School of Medicine
Arlene Stecenko, M.D. - Emory University School of Medicine

"I believe that the AerovectRx technology presents a unique opportunity to fulfill several critical unmet needs in the area of drug delivery and preventive medicine," said Dr. Brigham. "I look forward to contributing to the development of these products."

"This board of advisors represents some of the innovative and dedicated researchers in the field of respiratory care and aerosol drug delivery," said Matthew H.J. Kim, J.D., founder and CEO of AerovectRx. "Their advice and guidance has already proven invaluable as we develop our pipeline of novel respiratory drugs and drug delivery products."

The AerovectRx nebulizer technology, licensed from the CDC, delivers novel therapies and vaccines in an easy to breathe mist. The technology employs a disposable vibrating mesh that can be integrated as part of either a consumable user-filled or pre-filled medication cartridge, which is designed to improve compliance, facilitate improved dosage control and provide efficient aerosolization while minimizing risks of re-infection.

Pulmonary, or inhaled, drug delivery offers a significant improvement in the administration of certain drugs and, in some instances, provides new therapeutic options for the treatment of disease. Inhaled drugs are rapidly and painlessly delivered to the lung for treatment of local, respiratory diseases, or to the bloodstream for treatment of systemic diseases for quicker onset and fewer potential side effects than other traditional forms of drug delivery. The annual market for inhaled drug delivery is estimated at $20 billion.

Additional biographical summaries on the Company's Scientific Advisory Board may be found at www.AerovectRx.com. Members of the AerovectRx Scientific Advisory Board are compensated for their time and are independent of the company. Listing of the affiliated institutions by the respective members of the Scientific Advisory Board does not necessarily reflect an endorsement by those institutions.

About AerovectRx

AerovectRx Corporation is an aerosol therapeutic company providing unit-dose customizable and scalable delivery solutions using the air we breathe as the gateway for better living. Products under development by AerovectRx are designed to deliver a wide variety of therapies for respiratory and non-respiratory systemic conditions. Potential targeted therapeutic candidates for the AerovectRx technology include treatments for asthma, cystic fibrosis, pulmonary hypertension, chronic obstructive pulmonary disease (COPD), diabetes, pain management, and for delivery of vaccines and anti-viral drugs. For more information, visit www.aerovectrx.com.